Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction–Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group
- 15 March 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (6) , 1723-1727
- https://doi.org/10.1200/jco.2001.19.6.1723
Abstract
PURPOSE: Reverse transcription-polymerase chain reaction (RT-PCR)–based detection of tyrosinase mRNA is the most frequently used laboratory method for the detection of circulating tumor cells in melanoma patients. However, previously published results showed considerable variability in the PCR positivity rates. MATERIALS AND METHODS: We designed a collaborative study to assess the sensitivity, specificity, and clinical relevance of a new standardized RT-PCR–based enzyme-linked immunosorbent assay (ELISA) for the detection of circulating melanoma cells. Blood samples of healthy donors mixed with cells of a melanoma cell line were prepared in a blinded fashion, and aliquots were sent to seven participating laboratories experienced in RT-PCR. RESULTS: The results demonstrate a high sensitivity (1 melanoma cell/mL blood) and specificity (no false-negatives and 7.4% [2 of 28] false-positives) of the assay and a satisfactory rate of interlaboratory reproducibility. The analysis of aliquots of blinded samples derived from 60 melanoma patients identified tyrosinase mRNA in 17 of 60 (28.3%): three (20%) of 15 stage I patients, two (13.3%) of 15 stage II patients, five (35.7%) of 14 stage III patients, and seven (43.8%) of 16 stage IV patients. The interlaboratory reproducibility of positive samples, however, was extremely low and indicates the presence of low amounts of target mRNA. CONCLUSION: Reverse transcriptase-PCR ELISA has a high sensitivity and specificity for the detection of tyrosinase mRNA in peripheral blood cells. The low interlaboratory reproducibility for the detection of tumor cells in blood samples of melanoma patients, however, raises the question of relevance of this assay for clinical use.Keywords
This publication has 16 references indexed in Scilit:
- Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma.Journal of Clinical Oncology, 1998
- RT-PCR for Tyrosinase-mRNA-Positive Cells in Peripheral Blood: Evaluation Strategy and Correlation with Known Prognostic Markers in 123 Melanoma PatientsJournal of Investigative Dermatology, 1998
- Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study.Journal of Clinical Oncology, 1997
- Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients.Journal of Clinical Oncology, 1997
- The Analysis of Tyrosinase-Specific mRNA in Blood Samples of Melanoma Patients by RT-PCR Is Not a Useful Test for Metastic Tumor ProgressionJournal of Investigative Dermatology, 1997
- Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral bloodAnnals of Oncology, 1996
- The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reactionBritish Journal of Cancer, 1995
- Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to ImmunotherapyJournal of Immunotherapy, 1994
- Hematogenous Spread of Malignant Melanoma Cells in Different Stages of DiseaseJournal of Investigative Dermatology, 1993
- Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reactionThe Lancet, 1991